2014
DOI: 10.1309/ajcp0fkdp7envkev
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: When combined with morphologic observations, molecular studies will increase our understanding of the pathogenesis and morphomolecular signatures associated with specific neoplasms and provide new horizons for precision medicine and targeted therapies.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
18
0

Year Published

2014
2014
2018
2018

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 69 publications
(19 citation statements)
references
References 90 publications
1
18
0
Order By: Relevance
“…GNAQ p.T96S mutation has been reported in skin and prostate cancers [27, 28]. GNAS mutation identified in this study was the hotspot mutation p.R201C that is common in low-grade appendiceal mucinous neoplasm and pancreatic intraductal papillary mucinous neoplasm [29, 30]. Nonsense mutation of ARID2 p.R1273X in our study has been reported in esophageal and head/neck cancers [31, 32].…”
Section: Resultssupporting
confidence: 62%
“…GNAQ p.T96S mutation has been reported in skin and prostate cancers [27, 28]. GNAS mutation identified in this study was the hotspot mutation p.R201C that is common in low-grade appendiceal mucinous neoplasm and pancreatic intraductal papillary mucinous neoplasm [29, 30]. Nonsense mutation of ARID2 p.R1273X in our study has been reported in esophageal and head/neck cancers [31, 32].…”
Section: Resultssupporting
confidence: 62%
“…GNAS mutations are the second most common and occur in approximately 40-79% of IPMNs [53,54,55,56], and this can be used to differentiate IPMNs from other pancreatic cystic lesions including MCNs, solid pseudopapillary neoplasms, and serous cystic neoplasms [10]. RNF43 mutations are detected in 14-38% of IPMNs [53,55,56,57].…”
Section: Ipmnmentioning
confidence: 99%
“…SMADs mediate transcriptional responses to transforming growth factor ␤ (TGF-␤) and bone morphogenic protein (BMP) and are divided into 3 classes: the receptor-regulated SMADs that transmit TGF-␤ signaling (SMAD2 and -3) and bone morphogenetic protein signaling (SMAD1, -5, and -8), the inhibitory SMADs (SMAD6 and -7), and a common SMAD, SMAD4, that partners with the other SMADs to form the transcriptionally active trimeric complex (66). Inactivation of SMAD4 is common in pancreatic and colorectal cancers but less so in other human cancers (67,68). GSK-3 phosphorylation of SMAD4 has not been investigated.…”
Section: Establishment Of the Screening Assaymentioning
confidence: 99%